Evidence map›Paper›PMID 15385496›Full record

ArticleInfection and immunity2004

Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.

Patrícia A E Abreu, Patrícia A Miyasato, Mônica M Vilar, Waldely O Dias, Paulo L Ho, Míriam Tendler, Ana L T O Nascimento

Open access · greenAbstract read
In one paragraph

Article in Infection and immunity, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. HGPRT and PNP: Recombinant Enzymes fromPathogens (Basel, Switzerland) · 2023
    Article
  3. Article
  4. Article
  5. Review
  6. Tetanus toxin fragment C fused to flagellin makes a potent mucosal vaccine.Clinical and experimental vaccine research · 2015
    Article
  7. Current status of vaccines for schistosomiasis.Clinical microbiology reviews · 2008
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Patrícia A E AbreuCentro de Biotecnologia, Instituto Butantan, Universidade de São Paulo, Brazil.
Patrícia A Miyasato
Mônica M Vilar
Waldely O Dias
Paulo L Ho
Míriam Tendler
Ana L T O Nascimento
Instituto Butantan · BRFundação Oswaldo Cruz · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We have constructed vectors that permit the expression in Escherichia coli of Schistosoma mansoni fatty acid-binding protein 14 (Sm14) in fusion with the nontoxic, but highly immunogenic, tetanus toxin fragment C (TTFC). The recombinant six-His-tagged proteins were purified by nickel affinity chromatography and used in immunization and challenge assays. Animals inoculated with TTFC in fusion with or coadministered with Sm14 showed high levels of tetanus toxin antibodies, while animals inoculated with Sm14 in fusion with or coadministered with TTFC showed high levels of Sm14 antibodies. In both cases, there were no changes in the type of immune response (Th2) obtained with the fusion proteins compared to those obtained with the nonfused proteins. Mice immunized with the recombinant proteins (TTFC in fusion with or coadministered with Sm14) survived the challenge with tetanus toxin and did not show any symptoms of the disease. Control animals inoculated with either phosphate-buffered saline (PBS) or Sm14 died with severe symptoms of tetanus after 24 h. Mice immunized with the recombinant proteins (Sm14 in fusion with or coadministered with TTFC) showed a 50% reduction in worm burden when they were challenged with S. mansoni cercariae, while control animals inoculated with either PBS or TTFC were not protected. The results show that the expression of other antigens in fusion at the carboxy terminus of TTFC is feasible for the development of a multivalent recombinant vaccine.

Indexed as

Membrane Transport ProteinsSchistosoma mansoniAnimalsAntibodies, BacterialAntibodies, HelminthCarrier ProteinsFatty Acid Transport ProteinsHelminth ProteinsMiceMice, Inbred BALB CPeptide FragmentsRecombinant Fusion ProteinsSchistosomiasis mansoniSurvival RateTetanusTetanus ToxinAntibodies, BacterialAntibodies, HelminthCarrier ProteinsFatty Acid Transport ProteinsHelminth ProteinsMembrane Transport ProteinsPeptide FragmentsRecombinant Fusion ProteinsSM14 protein, Schistosoma mansoniTetanus Toxintetanus toxin fragment CVaccinesVaccines, Synthetic

Identifiers

PMID15385496
PMCPMC517564
OpenAlexW2110130122

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.